InsidersTradesSigma
Pharmanutra PR - First Sales on the US Market Stock: price and directors' dealings · Italy · Consob
Follow the Pharmanutra PR - First Sales on the US Market share price and the full management transaction log of the company, a publicly traded company based in Italy. Shares are listed on IT IT, under the oversight of Consob. Operating in the Health Care sector, Pharmanutra PR - First Sales on the US Market has published 1 insider filings. Market capitalisation: €861.8m. The latest transaction was reported on 3 October 2023 (Other). Among the most active insiders: Unknown. Every trade is free.
1
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Pharmanutra PR - First Sales on the US Market Strong Buy (bullish), based on 3 analysts. Average price target: €81.33.
Fundamental score
Ranked 8,059 of 26,212 companies
61.1
score / 100
Value37
Quality85
FCF yld1.9%
Earn yld2.3%
EV/EBITDA26.1x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 3 October 2023